JP2021502984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502984A5 JP2021502984A5 JP2020526504A JP2020526504A JP2021502984A5 JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5 JP 2020526504 A JP2020526504 A JP 2020526504A JP 2020526504 A JP2020526504 A JP 2020526504A JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- activation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025269754A JP2026040534A (ja) | 2017-11-15 | 2025-12-19 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17201762.6 | 2017-11-15 | ||
| EP17201762 | 2017-11-15 | ||
| EP18174634 | 2018-05-28 | ||
| EP18174634.8 | 2018-05-28 | ||
| PCT/EP2018/081296 WO2019096874A1 (en) | 2017-11-15 | 2018-11-15 | Factor x binders enhancing fx activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025269754A Division JP2026040534A (ja) | 2017-11-15 | 2025-12-19 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502984A JP2021502984A (ja) | 2021-02-04 |
| JP2021502984A5 true JP2021502984A5 (enExample) | 2021-12-02 |
| JP7841846B2 JP7841846B2 (ja) | 2026-04-07 |
Family
ID=64426877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526504A Active JP7841846B2 (ja) | 2017-11-15 | 2018-11-15 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
| JP2025269754A Withdrawn JP2026040534A (ja) | 2017-11-15 | 2025-12-19 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025269754A Withdrawn JP2026040534A (ja) | 2017-11-15 | 2025-12-19 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11787874B2 (enExample) |
| EP (2) | EP4667496A3 (enExample) |
| JP (2) | JP7841846B2 (enExample) |
| CN (2) | CN111386285B (enExample) |
| ES (1) | ES3050257T3 (enExample) |
| MA (1) | MA50893A (enExample) |
| WO (1) | WO2019096874A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CN111386285B (zh) * | 2017-11-15 | 2024-08-27 | 诺和诺德股份有限公司 | 增强fx活化的因子x结合物 |
| TWI772724B (zh) | 2018-12-21 | 2022-08-01 | 英商克馬伯有限公司 | 具有共同輕鏈的FIXaxFX雙專一性抗體 |
| CN115023440B (zh) | 2019-09-23 | 2025-09-12 | 特韦斯特生物科学公司 | 结合CD3ε的抗体 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| US12258406B2 (en) * | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| JP2025518552A (ja) * | 2022-05-16 | 2025-06-17 | セリントラ・セラピューティクス・エスア | 細胞を操作するための組成物及び方法 |
| MA71385A (fr) * | 2022-07-08 | 2025-04-30 | Novo Nordisk A/S | Composés isvd hautement puissants capables de remplacer fviii(a) |
| US12098400B2 (en) * | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| CN115960227B (zh) * | 2022-11-08 | 2026-06-16 | 河南赛诺特生物技术有限公司 | 一种抗人msh2的单克隆抗体及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| JPH08510555A (ja) | 1993-07-01 | 1996-11-05 | デイド、インターナショナル、インコーポレイテッド | 第ｘ因子除去血漿の調製のための方法 |
| WO2000007626A1 (en) | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| NZ540194A (en) * | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| PT1687338E (pt) | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| EP2824183B1 (en) | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| KR102069498B1 (ko) | 2007-09-28 | 2020-01-23 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법 |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| TW201625299A (zh) * | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物 |
| CA2978038A1 (en) | 2015-04-17 | 2016-10-20 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
| CA3027018A1 (en) | 2016-07-29 | 2018-02-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
| AU2017363309A1 (en) | 2016-11-23 | 2019-07-11 | Bioverativ Therapeutics Inc. | Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X |
| CN111386285B (zh) * | 2017-11-15 | 2024-08-27 | 诺和诺德股份有限公司 | 增强fx活化的因子x结合物 |
-
2018
- 2018-11-15 CN CN201880073999.9A patent/CN111386285B/zh active Active
- 2018-11-15 EP EP25187342.8A patent/EP4667496A3/en active Pending
- 2018-11-15 CN CN202411097090.0A patent/CN118745229A/zh active Pending
- 2018-11-15 EP EP18807239.1A patent/EP3710486B1/en active Active
- 2018-11-15 US US16/764,124 patent/US11787874B2/en active Active
- 2018-11-15 MA MA050893A patent/MA50893A/fr unknown
- 2018-11-15 ES ES18807239T patent/ES3050257T3/es active Active
- 2018-11-15 JP JP2020526504A patent/JP7841846B2/ja active Active
- 2018-11-15 WO PCT/EP2018/081296 patent/WO2019096874A1/en not_active Ceased
-
2023
- 2023-09-06 US US18/242,868 patent/US20230416404A1/en active Pending
-
2025
- 2025-12-19 JP JP2025269754A patent/JP2026040534A/ja not_active Withdrawn